ZA201905585B - Jak inhibitors containing a 4-membered heterocyclic amide - Google Patents

Jak inhibitors containing a 4-membered heterocyclic amide

Info

Publication number
ZA201905585B
ZA201905585B ZA2019/05585A ZA201905585A ZA201905585B ZA 201905585 B ZA201905585 B ZA 201905585B ZA 2019/05585 A ZA2019/05585 A ZA 2019/05585A ZA 201905585 A ZA201905585 A ZA 201905585A ZA 201905585 B ZA201905585 B ZA 201905585B
Authority
ZA
South Africa
Prior art keywords
membered heterocyclic
jak inhibitors
inhibitors containing
heterocyclic amide
amide
Prior art date
Application number
ZA2019/05585A
Other languages
English (en)
Inventor
Paul R Fatheree
Gary E L Brandt
Cameron Smith
Steven D E Sullivan
Orden Lori Jean Van
Melanie A Kleinschek
Glenn D Crater
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of ZA201905585B publication Critical patent/ZA201905585B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
ZA2019/05585A 2017-03-09 2019-08-23 Jak inhibitors containing a 4-membered heterocyclic amide ZA201905585B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
PCT/US2018/021489 WO2018165392A1 (en) 2017-03-09 2018-03-08 Jak inhibitors containing a 4-membered heterocyclic amide

Publications (1)

Publication Number Publication Date
ZA201905585B true ZA201905585B (en) 2020-05-27

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2019/05585A ZA201905585B (en) 2017-03-09 2019-08-23 Jak inhibitors containing a 4-membered heterocyclic amide
ZA2019/05618A ZA201905618B (en) 2017-03-09 2019-08-26 Fused imidazo-piperidine jak inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2019/05618A ZA201905618B (en) 2017-03-09 2019-08-26 Fused imidazo-piperidine jak inhibitors

Country Status (20)

Country Link
US (10) US10208040B2 (enExample)
EP (2) EP3592743A1 (enExample)
JP (2) JP6974487B2 (enExample)
KR (2) KR102526764B1 (enExample)
CN (2) CN110461839B (enExample)
AR (2) AR111241A1 (enExample)
AU (2) AU2018231032B2 (enExample)
BR (2) BR112019018648A2 (enExample)
CA (1) CA2997772A1 (enExample)
DK (1) DK3592742T3 (enExample)
EA (2) EA037261B1 (enExample)
ES (1) ES2882186T3 (enExample)
IL (2) IL268689B2 (enExample)
MX (2) MX388750B (enExample)
PH (2) PH12019501941A1 (enExample)
PT (1) PT3592742T (enExample)
SG (2) SG11201907840RA (enExample)
TW (2) TWI754019B (enExample)
WO (2) WO2018165395A1 (enExample)
ZA (2) ZA201905585B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
EP3831830A1 (en) * 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
TWI754019B (zh) * 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
DK3837258T3 (da) * 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR102873783B1 (ko) 2019-02-25 2025-10-21 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 Jak 억제제 화합물 및 그 사용
US12698289B2 (en) 2019-02-25 2026-08-04 Henan Medinno Pharmaceutical Technology Co., Ltd. Solid forms of pharmaceutically acceptable salts of (S)-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-4,6-dihydropyrrolo[3,4-d]imidazol-5(1H)-yl)(3-hydroxypyrrolidin-1-yl)methanone as JAK inhibitors
UA130579C2 (uk) 2019-03-05 2026-03-25 Інсайт Корпорейшн Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень
CN114901659A (zh) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
JP7580136B2 (ja) * 2019-12-30 2024-11-11 路良 Jak阻害剤化合物及びその使用
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
TW202317550A (zh) * 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形
CN117658852B (zh) * 2023-11-15 2026-03-24 西北工业大学 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用
WO2025157904A1 (en) * 2024-01-24 2025-07-31 Kiox Pharmaceuticals Aps Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof
CN118903009B (zh) * 2024-10-11 2025-01-21 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3831830A1 (en) * 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
TWI754019B (zh) * 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários

Also Published As

Publication number Publication date
MX2019010539A (es) 2019-10-21
NZ756823A (en) 2021-04-30
US10392386B2 (en) 2019-08-27
PH12019501985A1 (en) 2020-10-05
US10954237B2 (en) 2021-03-23
CN110461839A (zh) 2019-11-15
SG11201907840RA (en) 2019-09-27
US11667637B2 (en) 2023-06-06
US20180258087A1 (en) 2018-09-13
EA201992128A1 (ru) 2020-01-29
EA037261B1 (ru) 2021-03-01
TWI754019B (zh) 2022-02-01
WO2018165395A1 (en) 2018-09-13
IL268689B (en) 2022-10-01
AU2018231032B2 (en) 2021-08-19
JP2020510010A (ja) 2020-04-02
US20230063643A1 (en) 2023-03-02
AR111241A1 (es) 2019-06-19
DK3592742T3 (da) 2021-08-09
KR102526764B1 (ko) 2023-04-27
US20180258088A1 (en) 2018-09-13
US20210269436A1 (en) 2021-09-02
US10519153B2 (en) 2019-12-31
MX388749B (es) 2025-03-11
EA201992126A1 (ru) 2020-02-05
IL268689A (en) 2019-10-31
US11878977B2 (en) 2024-01-23
US10196393B2 (en) 2019-02-05
SG11201907544VA (en) 2019-09-27
BR112019018648A2 (pt) 2020-06-16
CN110382498B (zh) 2022-07-12
TW201840560A (zh) 2018-11-16
US20200216447A1 (en) 2020-07-09
TW201837037A (zh) 2018-10-16
AU2018231032A1 (en) 2019-09-05
IL268689B2 (en) 2023-02-01
US20190119275A1 (en) 2019-04-25
US20200181141A1 (en) 2020-06-11
ES2882186T3 (es) 2021-12-01
BR112019018649A2 (pt) 2020-04-07
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
US20220289737A1 (en) 2022-09-15
MX2019010541A (es) 2019-10-21
WO2018165392A1 (en) 2018-09-13
AU2018231035B2 (en) 2021-09-09
US20190127371A1 (en) 2019-05-02
JP2020510015A (ja) 2020-04-02
AU2018231035A1 (en) 2019-09-05
AR111242A1 (es) 2019-06-19
IL268679A (en) 2019-10-31
AU2018231032A8 (en) 2019-10-17
KR20190127798A (ko) 2019-11-13
US10208040B2 (en) 2019-02-19
JP6974487B2 (ja) 2021-12-01
EP3592742B1 (en) 2021-05-19
JP7134990B2 (ja) 2022-09-12
EA037748B1 (ru) 2021-05-18
EP3592743A1 (en) 2020-01-15
TWI779016B (zh) 2022-10-01
US11453668B2 (en) 2022-09-27
IL268679B (en) 2021-10-31
US10550118B2 (en) 2020-02-04
US11254669B2 (en) 2022-02-22
MX388750B (es) 2025-03-20
CN110382498A (zh) 2019-10-25
KR102533646B1 (ko) 2023-05-17
ZA201905618B (en) 2021-05-26
PT3592742T (pt) 2021-07-30
CA2997772A1 (en) 2018-09-09
EP3592742A1 (en) 2020-01-15
CN110461839B (zh) 2022-08-23
KR20190127796A (ko) 2019-11-13

Similar Documents

Publication Publication Date Title
IL268679B (en) JAK inhibitors containing a tetracyclic heterocyclic amide
ZA201905811B (en) Novel inhibitors
SG11202104206SA (en) New heterocyclic compounds
HUE067265T2 (hu) Heterociklusos vegyületek mint PRMT5 inhibitorok
IL255246A0 (en) Heterocyclic amides as kinase inhibitors
ZA201706710B (en) Heterocyclic compounds as lsd1 inhibitors
SI3595667T1 (sl) Farmacevtski sestavki, ki obsegajo zaviralec jak
SMT202200250T1 (it) Composti eterociclici come inibitori della pi3k-gamma
IL279949A (en) Heterocyclic MCT4 inhibitors
ZA201907136B (en) Ip6k inhibitors
SG11201710694YA (en) Bicyclic heterocyclic amide derivative
IL287876A (en) Jak inhibitors
IL266150A (en) Amide compounds as kinase inhibitors
PT3643718T (pt) Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL291611A (en) Jak inhibitors
PL3484875T3 (pl) Pochodne pirazoliloaminobenzimidazolu jako inhibitory JAK
IL290381A (en) Jak inhibitors
ZA201907792B (en) Heterocyclic compound
ZA201907793B (en) Heterocyclic compound
HK40015197A (en) Jak inhibitors containing a 4-membered heterocyclic amide
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201621825D0 (en) Electronic cigarette cartridges
GB201617996D0 (en) Electronic cigarette cartridges